$0.88
-0.02 (-2.00%)
Open$0.90
Previous Close$0.90
Day High$0.91
Day Low$0.87
52W High$1.62
52W Low$0.51
Volume—
Avg Volume636.5K
Market Cap48.18M
P/E Ratio—
EPS$-0.68
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+2,197.1% upside
Current
$0.88
$0.88
Target
$20.24
$20.24
$11.64
$20.24 avg
$22.20
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 7.82M | 7.64M | 6.13M |
| Net Income | -1,043,017 | -954,590 | -792,337 |
| Profit Margin | -13.3% | -12.5% | -12.9% |
| EBITDA | -1,028,959 | -906,364 | -702,614 |
| Free Cash Flow | -801,636 | -705,541 | -523,657 |
| Rev Growth | -3.5% | +15.6% | +20.8% |
| Debt/Equity | 1.41 | 1.39 | 1.07 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |